DYRK1A and diabetes mellitus: Given the established links between metabolic dysfunction, immune perturbations, and cognitive decline under diabetes-related conditions (Burokas and Mela, 2025), future studies should also evaluate whether targeted pharmacological modulation of kinases such as DYRK1A/B may offer parallel benefits in preserving cognitive function while maintaining metabolic control.